[ad_1]
Arcutis Biotherapeutics (ARQT) wants to eliminate a terrible trade-off for patients with eczema and psoriasis. And Arcutis stock investors are taking notice, sending shares sky-high over the past year. Topical steroids are a mainstay in treating itchy skin conditions like eczema and psoriasis. But they come with a host of side effects, including skin thinning and spider veins, decreased bone…
[ad_2]
Source link